RE: Trial Measure Criteria21 Aug 2020 09:11
It’s measured against specificity, i.e. is it specific to Covid or does it give false negatives and sensitivity i.e. does it detect it in all cases or does it give false negatives. It’s tested against a load of samples versus the gold standard reference test, current PCR, but possibly BAMS in future. You can then calculate the %s.
We’ve been told affimers are highly specific, so expect this to be high 90s, if not 100%. Sensitivity is the key one as we don’t want a test that results in a large number of infected people thinking they’re ok. However, for repeated mass screening it’s less important as rapid tests will still pick up infections when the viral load is high. This will ensure people isolate and break the transmission chains. 80% is the FDA benchmark for antigen tests. Anything over 90% is excellent, we’re aiming even higher.